UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C.  20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended  March 31, 2019

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                        to                     

 

Commission File No.    000-54917

 

NATUR INTERNATIONAL CORP.

(Exact name of registrant as specified in its charter)

 

WYOMING   45-5547692
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

Jachthavenweg 124

1081 KJ Amsterdam

The Netherlands

(Address of principal executive offices)

 

Registrant’s telephone number, including area code:  011 31 20 578 7700

 

Securities registered pursuant to Section 12(b) of the Act:  None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   (1) Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer  ☐ Accelerated filer ☐
Non-accelerated filer  ☐ Smaller reporting company  ☒
  Emerging Growth company ☒

 

If an emerging growth company, indicate by check mark whether the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered

common stock,

$0.001 par value per share 

  NTRU   

 OTC Markets Group Inc

(OTCQB Market)

  

As of May 15, 2019, there were 131,425,194 shares of common stock, par value $0.001, of the registrant issued and outstanding.

 

 

 

 

 

 

PART I - FINANCIAL INFORMATION

 

The Unaudited Consolidated Financial Statements of Natur International Corp., a Wyoming corporation (the “Company,” “Natur,” “we,” “our,” “us” and words of similar import) were prepared by management and commence on the following page, together with related notes.  In the opinion of management, the Unaudited Consolidated Financial Statements fairly present the financial condition of the Company.

 

Natur International Corp.

 

Index to Unaudited Financial Statements

 

Unaudited Consolidated Balance Sheets 2
   
Unaudited Consolidated Statements of Operations 3
   
Unaudited Consolidated Statements of Cash Flows 5
   
Notes to Unaudited Consolidated Financial Statements 6

 

1

 

 

NATUR INTERNATIONAL CORP.

UNAUDITED CONSOLIDATED BALANCE SHEETS

 

    NOTES   March 31,
2019
(unaudited)
    December 31,
2018
 
ASSETS                
Current Assets                
Cash and cash equivalents         18,600       128,364  
Accounts receivable         8,619       42,744  
Related party receivable   4     1,796       1,833  
Inventories         103,396       179,072  
Other current assets   5     78,492       99,535  
                     
Current assets held for disposal   13     339       377,628  
Total Current Assets         211,242       829,176  
                     
Non-Current Assets                    
Intangible asset         21,793       37,353  
Fixed assets         256,592       523,510  
Other assets         176,350       201,160  
Right-of-use asset         580,310       -  
Non-current assets held for disposal         -       51,165  
Total Non-Current Assets         1,035,045       813,188  
                     
TOTAL ASSETS         1,246,287       1,642,364  
                     
LIABILITIES AND MEMBERS’ DEFICIT                    
                     
Current Liabilities                    
Accounts Payable         1,341,652       1,127,345  
Accrued expenses & other contingent liabilities   6     623,318       583,161  
Related party other liabilities   7     2,217,440       2,032,705  
Related party other notes   8     1,062,426       1,072,849  
Convertible note payable   9     2,159,680       1,600,710  
Related party convertible note payable   10     11,436,228       11,671,743  
Operating lease liabilities         263,013       -  
Current liabilities held for disposal   13     151,267       887,126  
Total Current Liabilities         19,255,024       18,975,639  
                     
Non-Current Liabilities                    
Operating lease liabilities         314,994       -  
Total Non-Current Liabilities         314,994       -  
                     
TOTAL LIABILITIES         19,570,018       18,975,639  
                     
Retained Deficit                    
Common stock, $0.001 par value, 200,000,000 shares authorized, 131,424,194 and 129,049,192 issued and outstanding as of March 31, 2019 and December 31, 2018 respectively.         131,425       129,049  
Preferred stock A, $0.001 par value, 2,469.131 shares authorized, 2,397.131 and 2,469.131  issued and outstanding as of March 31, 2019 and December 31, 2018 respectively. Convertible to common stock at a 1:33,000 ratio.         2       2  
Preferred stock B, $0.001 par value, 100,000 shares authorized, 100,000 and 100,000 issued and outstanding as of March 31, 2019 and December 31, 2018 respectively. Convertible to common stock at a 1:1000 ratio.         100       100  
Additional Paid in Capital         5,575,055       5,174,269  
Total Shareholders’ deficit         (24,047,101 )     (22,299,570 )
Accumulated other comprehensive loss         16,788       (337,125 )
TOTAL DEFICIT         (18,323,731 )     (17,333,275 )
                     
LIABILITIES AND MEMBERS’ DEFICIT         1,246,287       1,642,364  

 

The accompanying notes are an integral part of these consolidated financial statements

 

2

 

 

NATUR INTERNATIONAL CORP.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

 

   

March 31,
2019

(unaudited)

    March 31,
2018
 
             
REVENUE     64,419       527,717  
                 
COST OF GOODS SOLD - RELATED PARTY     30,881       200,354  
COST OF GOODS SOLD     63,896       73,398  
      94,777       273,752  
                 
GROSS MARGIN     (30,358 )     253,965  
                 
OPERATING EXPENSES                
Wages & Salaries     264,729       443,381  
Selling, General & Administrative     1,402,410       1,114,867  
Amortization & depreciation     272,189       53,316  
                 
Total operating expenses     1,939,328       1,611,564  
                 
LOSS FROM OPERATIONS     (1,969,686 )     (1,357,599 )
                 
Interest expense     39,233       28,848  
                 
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES     (2,008,919 )     (1,386,447 )
                 
Income taxes     -       -  
                 
INCOME FROM CONTINUING OPERATIONS     (2,008,919 )     (1,386,447 )
                 
Discontinued operations (note 14)                
Gain on disposal of subsidiary     300,798       -  
Loss from operations of discontinued Component     (39,410 )     (792,737 )
                 
NET LOSS ATTRIBUTE TO SHAREHOLDERS     (1,747,531 )     (2,179,184 )
                 
Earnings Per Share     (0.01 )     (0.02 )
Diluted Earnings Per Share     (0.01 )     (0.02 )
                 
COMPREHENSIVE INCOME                
                 
Net Loss     (1,747,531 )     (2,179,184 )
Other comprehensive income     353,913       157,681  
                 
COMPREHENSIVE LOSS     (1,393,618 )     (2,021,503 )

 

The accompanying notes are an integral part of these consolidated financial statements

 

3

 

 

NATUR INTERNATIONAL CORP.

UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ DEFICIT

 

    Common stock     Preferred A     Preferred B     Other                    
    Number of Shares     Amount
(.001 par)
    Issued
shares
    Amount
(.001 par)
    Issued
shares
    Amount
(.001 par)
    Paid in
Capital
    Retained
deficit
    Accumulated
OCI
    Total  
Balance at December 31, 2017     115,759,999       115,760       -       -       -       -       3,316,560       (15,250,748 )     (1,114,812 )     (12,933,240 )
                                                                                 
Net Loss                                                             (7,048,822 )             (7,048,822 )
Recapitalization     13,289,193       13,289       2,469.131       2       100,000       100       1,857,709                       1,871,100  
Other comprehensive loss                                                                     777,687       777,687  
Balance at December 31, 2018     129,049,192       129,049       2,469.131       2       100,000       100       5,174,269       (22,299,570 )     (337,125 )     (17,333,275 )
                                                                                 
Net Loss                                                             (1,745,531 )             (1,745,531 )
Share-based compensation                                                     403,162                       403,162  
Conversion of Preferred A to Common stock     2,376,002       2,376       (72 )     -                       (2,376 )                     -  
Other comprehensive income                                                                     353,913       353,913  
Balance at March 31, 2019     131,425,194       131,425       2,397       2       100,000       100       5,575,055       (24,047,101 )     16,788       (18,323,731 )

  

The accompanying notes are an integral part of these consolidated financial statements

 

4

 

 

NATUR INTERNATIONAL CORP.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

    March 31,
2019 (unaudited)
    March 31,
2018
 
             
CASHFLOW FROM OPERATING ACTIVITIES            
Net Loss     (1,747,531 )     (2,179,184 )
Adjustments to reconcile net loss to net cash used in operating activities                
Lease expense     65,496       -  
Amortization & depreciation     267,819       53,316  
Stock based compensation     403,162       -  
Changes in:                
- Accounts receivable     34,125       212,016  
- Related party receivable     37       51,400  
- Inventories     75,676       383,483  
- Other current assets     21,043       (40,805 )
- Accounts payable     214,307       307,533  
- Lease liabilities     (67,045 )     -  
- Accrued expenses     152,367       (477,104 )
- Accrued expenses - related parties     187,049       (401,747 )
Net cash used in operating activities     (393,495 )     (2,091,092 )
Net cash used in operating activities - Discontinued operations     (358,570 )     (237,599 )
                 
CASHFLOW FROM INVESTING ACTIVITIES                
Cash paid for purchase of property and equipment     -       -  
Cash received for sale of property and equipment     -       -  
Net cash from in investing activities     -       -  
Net cash from in investing activities - Discontinued Operations     51,165       -  
                 
CASHFLOW FROM FINANCING ACTIVITIES                
                 
Related party loan additions     -       12,330  
Convertible loan note additions     560,915       -  
Related party convertible loan note additions     -       1,233,046  
Net cash provided from financing activities     560,915       1,245,376  
Net cash from financing activities - Discontinued Operations     -       41,118  
                 
Effect of foreign exchange rate changes on cash and cash equivalents    

30,221

      157,681  
                 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS     (109,764 )     (884,516 )
                 
CASH AND CASH EQUIVALENTS beginning of period     128,364       1,082,734  
CASH AND CASH EQUIVALENTS end of period     18,600       198,218  

 

The accompanying notes are an integral part of these consolidated financial statements

 

5

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

 

Natur International Corp was formerly named Future Healthcare of America. Future Healthcare of America was founded in 2012 and was traded with stock ticker symbol FUTU. Future Healthcare of America was a provider of home healthcare services, including senior care, occupational and speech therapy, and pediatric nursing services.

 

The name change took place following the consummation of acquisition of Natur Holding B.V. and became effective Monday, January 7. The stock ticker symbol has become NTRU. Currently the healthcare services are being wound down.

 

Natur Holding B,V. (“we”, “our”, “the Company” or “Natur”) was founded in late 2015 and has its headquarters in Amsterdam, the Netherlands.

 

At the onset of the quarter, our product line up centered on a range of cold pressed juices and healthy snacks. These products were sold either directly or through distribution partners in the Netherlands and the United Kingdom. Beginning in the fourth quarter of 2018, and throughout the first quarter of 2019, the Company focus shifted from dependence on the legacy fruit and vegetable juices and snacks toward innovating a new line of hemp-derived natural food and beverage products. The Company products value proposition is to affordably provide the most culturally relevant, authentic, fresh fruit, vegetable and hemp-derived supplement consumer products to democratize clean, healthy, eating and drinking occasions, with plans to address the growing needs for products that address other personal needs in health, wellness and beauty care.

 

Through third party contract manufacturers, we apply patented technology to proprietary nutrient dense blends of fruit and vegetables, adding hemp-derived supplements. These are bottled or packed with technically advanced food and product safety measures and in some cases cold high-pressure processing to bring fresh tasting fruit, vegetable and hemp-derived supplement blends to market through more than fifteen product types. These newly innovated products are brought to market through Natur’s distribution channels of direct-to-business, direct-to-consumer and through select distributors.

 

Natur operated as a private enterprise in the Netherlands from its founding in 2015 through November 13, 2018, when it was acquired as a wholly owned subsidiary in a share exchange transaction by Future Healthcare of America on November 13, 2018, contemplated by that certain Share Exchange Agreement, among the Company and the former shareholders of Natur Holding, B.V. (the “Share Exchange Transaction”). In connection with the Share Exchange Transaction, the former shareholders of Natur received the equivalent of 215,759,999 shares of the Common Stock (the “Common Stock”), which was issued in part as 115,760,000 shares of Common Stock and in part as 100,000 shares of voting, convertible Series B Preferred Stock (the “Series B Preferred Stock”) representing 100,000,000 shares of Common Stock upon conversion. The Series B Preferred Stock will convert automatically upon the Company increasing the number of shares of Common Stock of its authorized capital, which it plans to do promptly so as to cause the conversion of the Series B Preferred Stock. Immediately after the Share Exchange Transaction, the former Natur shareholders collectively own the controlling position among the shareholders of the Company

 

The merger was accounted for as a reverse capitalization with Natur Holding BV being treated as the accounting acquirer. As such, the historical information for all periods presented prior to the merger date relate to Natur Holding BV. Subsequent to the merger date, the information relates to the consolidated entities of Natur with its subsidiary Natur Holding BV and the former subsidiaries of Future Healthcare of America, that are currently in the process of being wound down and presented as discontinued operations.

 

In connection with the acquisition, net cash received was $2,000,000 and costs incurred were $399,381 including professional fees for legal, accounting services and finance commission.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation. The Company prepares its financial statements using the accrual basis of accounting in accordance with United States generally accepted accounting principles (“US GAAP”).

 

Consolidation - The financial statements presented reflect the accounts of Natur Holding B.V. and it’s direct or indirect subsidiaries. All inter-company transactions have been eliminated in consolidation.

 

Use of Estimates in Financial Statement Preparation. The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

  

Cash and Cash Equivalents. Cash equivalents include all highly liquid investments with original maturities of three months or less.

 

Accounts Receivable. Accounts receivable are comprised of unsecured amounts due from customers. The Company carries its accounts receivable at their face amounts less an allowance for bad debts. The allowance for bad debts is recognized based on management’s estimate of likely losses per year, based on past experience and review of customer profiles and the aging of receivable balances.

 

6

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

 

Inventory. Inventory, consisting of raw materials, work in progress and finished goods, is valued at the lower of the inventory’s costs or net realizable value, using the first in, first out method to determine the cost. Management compares the cost of inventory with its net realizable value and an allowance is made to write down inventory to net realizable value, if lower.

 

Property and Equipment . Property and equipment are valued at cost. Additions are capitalized and maintenance and repairs are charged to expense as incurred. Gains and losses on dispositions of equipment are reflected in operations. Depreciation is provided using the straight-line method over the estimated useful lives of the assets as follows:

 

Category   Estimated Useful lives
Building and improvements   5 years
Machines and installations   5 years
Furniture and fixtures   7 years
Hardware and software   3 years

 

Intangible Assets, and Long-Lived Assets. The Company recognizes an acquired intangible asset apart from goodwill whenever the intangible asset arises from contractual or other legal rights, or when it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their useful lives. Impairment losses are recognized if the carrying amount of an intangible asset subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.

 

The Company’s long-lived assets, including intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Long lived assets are evaluated on a yearly basis and no impairment losses were incurred during the three months ended March 31, 2019. 

  

Related Party Transactions. The Board of Directors has adopted a Related Party Transaction Policy for the review of related person transactions. Under these policies and procedures, the management reviews related person transactions in which we are or will be a participant to determine if they are fair and beneficial to the Company. Financial transactions, arrangements, relationships or any series of similar transactions, arrangements or relationships in which a related person has or will have a material interest and that exceeds the lesser of: (i) $10,000, and (ii) one percent of the average of the Company’s total assets at year-end for the last two completed fiscal years, in the aggregate per year are subject to the boards review. Any member of the board who is a related person with respect to a transaction under review may not participate in the deliberation or vote requesting approval or ratification of the transaction. Transactions that are subject to the policy include any transaction, arrangement or relationship (including indebtedness or guarantees of indebtedness) in which the Company is a participant with a related person. The related person may have a direct or indirect material interest in the transaction. It is Company policy that the board shall approve any related party transaction before the commencement of the transaction. However, if the transaction is not identified before commencement, it must still be presented to the board for their review and ratification.

 

7

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

 

Revenue Recognition. Beginning on January 1, 2018, the Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle:

 

Step 1: Identify the contract with the customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when the company satisfies a performance obligation

 

The Company’s performance obligations are satisfied at the point in time when products are received by the customer, which is when the customer has title and the significant risks and rewards of ownership. Therefore, the Company’s contracts have a single performance obligation (shipment of product). The Company primarily receives fixed consideration for sales of product.

 

The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon delivery to the customer. The Company’s performance obligations are satisfied at that time.

 

Share-Based Payment Arrangement. The Company measures the cost of employee services received in exchange for an award of equity instruments (share-based payments, or SBP) based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the SBP award—the requisite service period (vesting period). For SBP awards subject to conditions, compensation is not recognized until the performance condition is probable of occurrence. The grant-date fair value of share options is estimated using the Black-Scholes-Merton option-pricing model. The Company adopted ASU 2018-07 in the first quarter of 2019 which aligns the accounting for share-based payment awards issued to employees and non-employees.

 

The fair value of each option granted during the period ended March 31, 2019 was estimated on the date of grant using the Black-Scholes-Merton option-pricing model with the weighted average assumptions in the following table:

 

    2019  
Expected dividend yield     0 %
Expected option term (years)     6  
Expected volatility     382 %
Risk-free interest rate     3 %

 

The expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected volatility was based on the volatility in the trading of the Company’s common stock. The assumed discount rate was the default risk-free six-year interest rate in the Netherlands.

 

8

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

 

Revenues do not include sales or other taxes collected from customers.

 

The Company’s products are sold and distributed through various channels, which include selling directly to retail stores and other outlets such as food markets, institutional accounts and independent outlets. The Company typically collects payment from customers within 30 days from the date of sale. The following table presents our continued revenues disaggregated by geographical region for the period ended March 31, 2019:

 

   

March 31,

2019

 
Netherlands     64,419  
France     -  
Iceland     -  
Total     64,419  

 

The Company sells its products and extends credit, generally without requiring collateral, based on an ongoing evaluation of the customer’s business prospects and financial condition. The Company evaluates the collectability of its trade accounts receivable based on a number of factors, including the Company’s historic collections pattern and changes to a specific customer’s ability to meet its financial obligations. The Company has established an allowance for doubtful accounts to adjust the recorded receivable to the estimated amount the Company believes will ultimately be collected.

 

The nature of the Company’s contracts does not give rise to variable consideration, such as prospective and retrospective rebates.

 

The Company experiences customer returns primarily as a result of damaged or out-of-date product. At any given time, the Company estimates less than 1% of sales could be at risk for return by customers. As the company do not deem this amount to be material no provision was recorded for the period ended 31 March, 2019. Returned product is recognized as a reduction of net sales.

 

Recent Accounting Pronouncements

 

Compensation—Stock Compensation: On June 20, 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to employees and nonemployees. Under ASU No. 2018-07, the existing employee guidance will apply to nonemployee share-based transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. In addition, the contractual term will be able to be used in lieu of an expected term in the option-pricing model for nonemployee awards. The adoption had no impact on the Company’s historic financial statements.

 

Leases: In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. This update requires the recognition of lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous guidance. The accounting for finance leases (capital leases) was substantially unchanged. The original guidance required application on a modified retrospective basis with adjustments to the earliest comparative period presented. In August 2018, the FASB issued ASU No. 2018-11, “Targeted Improvements to ASC 842,” which included an option to not restate comparative periods in transition and elect to use the effective date of ASU No. 2016-02 as the date of initial application, which the Company elected. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, and continues to be reported under previous guidance that did not require the recognition of operating lease liabilities and corresponding lease assets on the consolidated balance sheet. As a result of the adoption of ASU No. 2016-02 on January 1, 2019, the Company recorded operating lease right-of-use assets of $580,310 and operating lease liabilities of $578,007. The adoption of ASU No. 2016-02 had an immaterial impact on the Company’s condensed consolidated statement of income and c consolidated statement of cash flows for the three-month period ended March 31, 2019. In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company to carry forward the historical lease classification, not reassess prior conclusions related to expired or existing contracts that are or that contain leases, and not reassess the accounting for initial direct costs.

 

9

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

 

Foreign Currency Translation. The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

 

The financial records of the Company are maintained in its local currency, the euro (“EUR”), which is the functional currency. Assets and liabilities are translated from the local currency into the reporting currency, U.S. dollars, at the exchange rate prevailing at the balance sheet date. Revenues and expenses are translated at weighted average exchange rates for the period to approximate translation at the exchange rates prevailing at the dates those elements are recognized in the consolidated financial statements. Foreign currency translation gain (loss) resulting from the process of translating the local currency financial statements into U.S. dollars are included in determining accumulated other comprehensive income in the consolidated statement of stockholders’ equity.

 

10

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

 

Unless otherwise noted, the rate presented below per U.S. $1.00 was the midpoint of the interbank rate as quoted by OANDA Corporation (www.oanda.com) contained in its consolidated financial statements. Translation of amounts from EUR into U.S. dollars has been made at the following exchange rates for the respective periods:

 

    March 31,
2019
    December 31,
2018
 
Balance Sheets     0.8914       0.8734  
Statements of operations and comprehensive income (loss)     0.8805       0.8464  
Equity     0.9037       0.9037  

 

Cost of Revenues. Cost of revenue includes all direct expenses incurred to produce the revenue for the period. This includes, but is not limited to, costs for finished products, pick packing costs, storage costs and transportation costs. Cost of revenues are recorded in the same period as the resulting revenue.

 

Employee Benefits. Wages, salaries, bonuses and social security contributions are recognized as an expense in the year in which the associated services are rendered by employees. For any unused portion of vacation leave, an accrual is recorded for carry over to the following year.

 

Income Taxes. The Company is subject to US corporation tax. The US combined federal and state corporate tax rate is 23%. The company’s United States net operating losses totaled $3,483,928 as of December 31, 2017 and begin to expire in tax years 2032 and following. Net losses from US operating totaled $157,386 for 2018 and may be carried forward indefinitely. The company is subject to US Internal Revenue Code rules limiting the use of US net operating losses after the merger with Future Health Care of America during 2018 (described in Note 17). This limitation has no effect on the Company’s financial statements because the Company has recognized no deferred tax asset with respect to its net operating loss carryforwards. The NOLs are the cumulative NOL’s per the Company’s 2017 federal income tax return. The 382 limit will not be factored in until the company has income and the limit is therefore applicable.

 

Natur Holding, the Dutch subsidiary of Natur International Corp is structured as a Dutch limited liability company. Tax on the result is calculated based on the result before tax in the profit and loss account, taking into account losses available for set-off from previous years (to the extent that they have not already been included in the deferred tax assets) and exempt profit components and after the addition of non-deductible costs. Due account is also taken of changes which occur in the deferred tax assets and deferred tax liabilities in respect of changes in the applicable tax rate.

 

The corporate tax rate for profits above $238,812 (or €200,000) amounts to 25%. Below that amount the rate is 20%. Future profits can be carried back to prior year losses for a maximum of 9 years for the full amount of losses incurred.

 

In the financial statements of group companies, a tax charge is calculated on the basis of the accounting result. The corporate income tax that is due by these group companies is charged into the current accounts of the company.

 

Because of the compensable losses no deferred taxes are included in the financial statements. From incorporation of the company only the Corporation Tax return of 2015/2016 has been filed. All years are still subject to examination.

 

Fair Value of Financial Instruments. The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, and short-term notes approximate fair value due to the relatively short period to maturity for these instruments. The long-term debt approximate fair value since the related rates of interest approximate current market rates.

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs.

 

The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

 

Income /(Loss) Per Share  - The Company computes income (loss) per share in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260 Earnings Per Share, which requires the Company to present basic earnings per share and diluted earnings per share when the effect is dilutive (see Note 13).

 

11

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 3 – GOING CONCERN

 

The Company considered its going concern disclosure requirements in accordance with ASC 240-40-50. The Company concluded that its negative working capital and decreased cash flows from operations are conditions that raised substantial doubt about the Company’s ability to continue as a going concern. Without a successful plan in place from management these conditions could negatively impact the Company’s ability to meets its financial obligations over the next year. In response, the Company has implemented a plan to alleviate such reasonable doubt as follows: (i) the Company will continue to generate additional revenue (and positive cash flows from operations) partly related to the Company’s expansion into new product lines during 2019 and partly related to the Company wide sales initiatives already implemented; (ii) in addition cost saving initiatives and an organization restructuring program that is almost completed, will have an additional positive impact on the cost-basis of the organization. Notwithstanding the foregoing, the Company will seek capital as needed, which may be either equity or debt, or both. The Company does not have any capital sources determined at this time, and capital may not be available when sought. The accompanying financial statements have been prepared assuming that the company will continue as a going concern. The company is currently undertaking a corporate restructuring exercise, which is further disclosed in Note 15 – subsequent events.

 

NOTE 4 – RELATED PARTY RECEIVABLES

 

Receivables of related parties at March 31, 2019 and December 31, 2018 consisted of the following:

 

    March 31,
2019
    December 31,
2018
 
             
Micknifisent B.V.     1,796       1,833  
      1,796       1,833  

 

NOTE 5 – OTHER CURRENT ASSETS

 

Other current assets at March 31, 2019 and December 31, 2018 consisted of the following:

 

    March 31,
2019
    December 31,
2018
 
             
Value Added Tax receivable     62,851       67,388  
Prepaid expenses     15,550       32,054  
Other Receivables     91       93  
      78,492       99,535  

 

12

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 6 – ACCRUED EXPENSES & OTHER CONTINGENT LIABILITIES

 

Accrued expenses & other contingent liabilities at March 31, 2019 and December 31, 2018 consisted of the following:

 

    March 31,
2019
    December 31,
2018
 
             
Taxes payable     534,254       352,423  
Invoices to be received     25,572       3,972  
Holiday Allowance Payable     33,584       24,642  
Other accrued expenses & other contingent liabilities     29,908       202,124  
      623,318       583,161  

 

NOTE 7 – RELATED PARTY OTHER LIABILITIES

 

Related party other liabilities at March 31, 2019 and December 31, 2018 consisted of the following:

 

    March 31,
2019
    December 31,
2018
 
             
NL Life Sciences B.V.     829,942       563,118  
STB Family Offices SARL     196,193       200,234  
STB Family Offices B.V.     653,190       661,432  
Stichting Thank You Nature     -       16,913  
Flare Media B.V.     24,944       25,458  
AMC     238,945       325,382  
Management & Board Fees     251,910       142,154  
Yoomoo Limited     -       98,014  
Dynamic Health B.V.     22,316       -  
      2,217,440       2,032,705  

 

For the outstanding amount relating to AMC this transaction relates to the purchase of bottled juices for resale. Total purchases relating to goods sold for the three-month period ended March 31, 2019 and the three-month period ended March 31, 2018 was $31,726, and $581,997, respectively.

 

For the loan from NL Life Sciences and STB Family Offices there is no repayment schedule in place. The interest rate is charged on the basis of EURIBOR + 3% on the average balance of the loan.

 

The other loans consist of the procurement of juices and consulting fees for the management team. No interest is being charged.

 

13

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 8 – RELATED PARTY OTHER NOTES

 

Loan from other related parties at March 31, 2019 and December 31, 2018 consisted of the following:

 

    March 31,
2019
    December 31,
2018
 
             
Efficiency Life Fund     392,641       400,750  
TriDutch Holding B.V.     669,785       672,099  
      1,062,426       1,072,849  

 

For the loan from Tridutch Holding B.V., there is no repayment schedule in place. The interest rate is charged on the basis of EURIBOR + 3% on the average balance of the loan. In 2018 accrued interest of $17,249 was added to the balance and additional borrowings of $128,043 were drawn down, partly offset by a positive exchange rate difference of $25,283. In 2019 accrued interest of $2,314 was added to the balance and no additional borrowings were drawn down, no repayments were made on the balance in either 2018 or 2019.

 

For the loan from Efficiency Life Fund is a repayment schedule in place to repay the loan in 10 installments from July 2019 to April 2020. The entire balance of 400,750 was drawn down in 2018 with no repayments made on the balance to date. The movement in 2019 relates wholly to exchange rate difference.

 

NOTE 9 – CONVERTIBLE NOTE PAYABLE

 

Convertible loans payable at March 31, 2019 and December 31, 2018 consisted of the following:

 

    March 31,
2019
    December 31,
2018
 
             
Convertible loan 1     632,695       629,750  
Convertible loan 2     962,285       970,960  
Convertible loan 3     564,700       -  
      2,159,680       1,600,710  

 

Convertible Loan 1

 

Party for loan 1 has granted a loan facility in the principle amount of $581,058 or €500,000 with the right, but not the obligation to convert the outstanding loan amounts into shares in the capital of Natur at a company valuation of $17.4 million or €15 million for a term from December 19, 2017, till the maturity date of December 31, 2018, at an interest rate of 10% per annum. No further drawdowns were made on the loan in 2018 or 2019 and the increased balance is due to the accrued interest as no repayment for capital or interest have been made. The lender has agreed to a term sheet for conversion of the debt into common stock at May 7, 2019. Please refer to Note 15, subsequent events.

 

Convertible Loan 2

 

On October 20, 2017, an amount of $929,692 or €800,000 was advanced to the Company for a loan agreement that was drafted but never signed. An interest rate of 5% per annum is calculated and the loan has a maturity date of February 28, 2018. The loan is convertible to shares of Natur at a company valuation of $23.3 million or €20 million. The loan is in default and lender has demanded payment and does not want to convert. No further drawdowns were made on the loan in 2018 or 2019 and the decreased balance is due to favorable movement in the exchange rate offsetting the additional accrued interest as no repayment for capital or interest have been made.

 

Convertible Loan 3

 

Natur Holding BV, the principle subsidiary of Natur International Corp, entered into a loan agreement with Dam! Holding BV, under which Natur Holding may borrow up to US$560,915 or €500,000. The final terms of the agreement were concluded on February 18, 2019.The full drawdown of US$560,915 was made in three tranches throughout January and February 2019 and was used for general expenses of Natur Holding and a partial repayment of their major supplier, as provided in the loan agreement. The loan amount can be made in Euros, in the same numeric amounts if certain additional conditions are met by Natur Holdings related to further capital restructuring of Natur Holdings, which the company has already undertaken.

 

Repayment is due after six months from the date of receipt of the initial funds in the Natur Holding’s account. The loan may be pre-paid in full or in part at any time. Interest, at the rate of 5% per annum, is due and payable quarterly. The loan carries a default interest rate of 11% per annum. The loan has the typical default provisions of a borrowing arrangement, including breach of the borrower obligations, bankruptcy of the borrower, significant changes in the borrower’s business, and dissolution of the borrower. The full amount of the loan is covered by the grant of a security interest in Natur Holdings.

 

The loan amount, if unpaid at maturity, may be converted into common stock of Natur International Corp. at the conversion price of $0.05 per common stock. The lender has agreed to a term sheet for conversion of the debt into common stock at April 29, 2019. Please refer to Note 15, subsequent events.

 

14

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 10 – RELATED PARTY CONVERTIBLE NOTE PAYABLE

 

Related party convertible note payable at March 31, 2019 and December 31, 2018 consisted of the following:

 

    March 31,
2019
    December 31,
2018
 
Convertible loan Efficiency Life Fund     11,436,228       11,671,743  

 

The convertible loan has been converted in the subsequent period. $8,671,743 of the balance was settled, using series C preferred shares and the remaining $3,000,000 was converted into long term debt. Please refer to Note 15, subsequent events.

 

NOTE 11 – OPTIONS & WARRANTS

 

On November 13, 2018, the Company closed a Subscription Agreement with Alpha Capital Anstalt wherein the Company granted the following warrants to purchase:

 

-A total of 33,000,000 shares of common stock, at $0.0606060 per share, exercisable for four years.

-A total of 6,000,000 shares of common stock, at $0.15 per share, exercisable for four years.

 

A summary of the status of the warrants granted is presented below for the three months ended:

  

    March 31, 2019     December 31, 2018  
    Shares     Weighted
Average
Exercise Price
    Shares     Weighted
Average
Exercise Price
 
Outstanding at beginning of period     39,000,000     $ 0.074       -     $ -  
Granted     -       -       39,000,000       0.074  
Exercised     -       -       -       -  
Expired     -       -       -       -  
Outstanding at end of period     39,000,000     $ 0.074       39,000,000     $ 0.074  

 

On January 16, 2019, the company completed compensatory arrangements with three board members of Natur International Corp. with the following terms:

 

Mr. Anthony Joel Bay, through La Bay Ventures Inc., will be issued a six-year option to purchase an aggregate of 7,319,321 shares of common stock of NTRU. The option granted by NTRU provides for equal quarterly vesting of the shares commencing March 31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at the election of NTRU. If the service agreement is terminated for a breach thereof, all vested and unvested options will terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable for the full term.

 

Mr. Rudolf Derk Huisman, through Pas Beheer BV, will be issued a six-year option to purchase an aggregate of 7,319,321 shares of common stock of NTRU. The option granted by NTRU provides for equal quarterly vesting of the shares commencing March 31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at the election of NTRU. If the service agreement is terminated for a breach thereof, all vested and unvested options will terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable for the full term.

 

15

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 11 – OPTIONS & WARRANTS - continued

 

Mr. Robert A. Paladino, through Cavalier Aire LLC., will be issued a six-year option to purchase an aggregate of 7,319,321 shares of common stock of NTRU. The option granted by NTRU provides for equal quarterly vesting of the shares commencing March 31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at the election of NTRU. If the service agreement is terminated for a breach thereof, all vested and unvested options will terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable for the full term.

 

A summary of the status of the share options is presented below for the three months ended:

 

    March 31, 2019     December 31, 2018  
    Shares     Weighted Average Fair Value     Shares     Weighted Average Fair Value  
Outstanding at beginning of period     -     $ -       -     $ -  
Vested     1,829,844       0.071       -       -  
Unvested     20,128,119                          
Exercised     -       0.071       -       -  
Expired     -       -       -       -  
Outstanding at end of period     21,957,963     $ 0.071       -     $ -  

 

The fair value of all stock options outstanding at 31 March, 2019 is $1,559,013 at a weighted average fair value of $0.071 per option.

 

NOTE 12 – LEASES

 

The Company leases identified assets comprising real estate.  Real estate leases consist primarily of office space. At the inception of a contract, the Company assesses whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the term, and (3) whether the Company has the right to direct the use of the asset. At inception of a lease, the Company allocates the consideration in the contract to each lease and non-lease component based on the component’s relative stand-alone price to determine the lease payments. Lease and non-lease components are accounted for separately.

 

Leases are classified as either finance leases or operating leases based on criteria in Accounting Standards Codification (“ASC”) 842. The Company’s operating leases are generally comprised of real estate. Operating leases are included shown separately in the unaudited consolidated balance sheet. On adoption of ASC 842 the Company recorded operating lease right-of-use assets of $580,310 and operating lease liabilities of $578,007. We do not believe the standard will materially affect our consolidated net earnings.

 

Right-of-use (“ROU”) assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company’s leases generally do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the implicit rate cannot be determined. ROU assets also include any lease payments made and exclude lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

  

Lease expense for operating leases, consisting of lease payments, is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the ROU asset on a straight-line basis over the asset’s estimated useful life and interest expense calculated using the amortized cost basis.

 

The Company’s leases have remaining lease terms of less than 3 years, which include options to extend the leases for up to five years, and some of which include options to terminate the leases within one year.  The Company has elected not to recognize ROU assets and lease liabilities for short-term operating leases that have a term of 12 months or less. The effect of short-term leases on the Company’s ROU assets and lease liabilities was not material.

 

Operating Lease Assets and Liabilities

 

    March 31, 2019     Balance Sheet Classification
Lease Assets   $ 580,310     Right-of-use Asset
             
Current lease liabilities     263,013     Operating lease liabilities
Non-current lease liabilities     314,994     Operating lease liabilities
Total Lease Liabilities   $ 578,007      

 

Maturity of Operating Lease Liabilities

 

  March 31, 2019  
2019   $ 196,034  
2020     270,649  
2021     178,323  
         
Total lease payments     645,006  
Less imputed interest     66,999  
         
Present value of lease liabilities   $ 578,007  

 

As of March 31, 2019, our operating leases have a weighted-average remaining lease term of 2.25 years and a weighted-average discount rate of 4%.

 

The future minimum obligations under operating leases in effect as of December 31, 2018 having a noncancelable term in excess of one year as determined prior to the adoption of ASC 842 are as follows:

 

2019     436,657  
2020     392,004  
2021     146,759  
2022     -  
2023     -  
Thereafter     -  
Total     975,430  

 

 

16

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 13 – LOSS PER SHARE

 

At March 31, 2019 the Company had 131,425,194 shares issues and outstanding at a nominal value of $.001. besides that, the Company has 2,397.130 preferred A shares and 100,000 preferred B shares.  Alpha capital Anstalt has two outstanding warrants issued at November 13, 2018 with 4 years term. The first warrant has an exercise price of $0.0606 for 36,000,000 shares the second warrant is 6,000,000 at $0.15 exercise price, the company has reserved 16,240,000 shares for management and Employee Stock Ownership Plan. At December 31, 2018, the Company had 129,049,192 shares of common stock issued and outstanding.

 

Because the company is in a net loss position, basic and diluted earnings per share are the same as the inclusion of potential dilutable shares would be anti-dilutive.

 

NOTE 14 – DISCONTINUED OPERATIONS AND ASSETS/LIABILITIES HELD FOR DISPOSAL

 

Effective November 30, 2018, the Company has closed down the London office and shops as part of the restructuring plan. Functionally the operations were shut down before December 31, 2018 and therefore we have qualified it as discontinued operations the sale of assets is in process. The existing support functions have been transferred to the headquarters in Amsterdam as part of the centralization of support staff initiative.

 

As of March 22, 2019 the company Naturalicious UK Limited has been put into liquidation and the matters are being dealt with by a qualified administration firm in the United Kingdom. A board meeting was held on March 22, 2019 with all creditors and it was agreed to liquidate the company. At this moment in time the rights & obligations of the company are handled by the administration firm and the legal obligation over the liabilities are extinguished. As the parent company no longer has any rights or obligations to the subsidiary it has been removed from the consolidation and the net liability position of the company is released and recognized as a gain on disposal.

 

Effective August 31, 2018, Natur International Corp closed the offices of its Casper, Wyoming operations. The increase in costs coupled with a decrease in business activity, lead to the decision to close the Casper, Wyoming operations. In closing the office, the Company transitioned its clients to new service providers, and terminated employees as the transition happened. The month to month lease was terminated with the landlord on August 31, 2018, and the office was closed the same day. We have one part-time employee, working remotely, primarily on the collection of accounts receivable.

 

17

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 14 – DISCONTINUED OPERATIONS AND ASSETS/LIABILITIES HELD FOR DISPOSAL - continued

 

The following table presents the carrying amounts of the major classes of assets and liabilities included in our discontinued operations as presented on our Unaudited Consolidated Balance Sheet as of March 31, 2019.

 

NATUR INTERNATIONAL CORP

UNAUDITED BALANCE SHEET OF DISCONTINUED OPERATIONS

 

    March 31,
2019
    December 31,
2018
 
Current assets            
Cash and cash equivalents     -       -  
Related party receivable     -       201,907  
Accounts receivable     339       124,016  
Inventories     -       -  
Other current assets     -       51,705  
Total current assets     339       377,628  
                 
Fixed Assets                
Tangible fixed assets     -       27,547  
Financial Fixed Assets     -       23,618  
Total fixed assets     -       51,165  
                 
TOTAL ASSETS     339       428,794  
                 
Current Liabilities                
Accounts Payable     25,692       643,616  
Accrued expenses & other contingent liabilities     125,575       243,510  
Total Liabilities     151,267       887,126  

 

NATUR INTERNATIONAL CORP

UNAUDITED INCOME STATEMENT OF DISCONTINUED OPERATIONS

 

    March 31,
2019
 
       
REVENUE     -  
         
COST OF GOODS SOLD     -  
         
GROSS MARGIN     -  
         
OPERATING EXPENSES        
Wages & Salaries     -  
Selling, General & Administrative     39,410  
Amortization & depreciation     -  
         
Total operating expenses     39,410  
         
LOSS FROM OPERATIONS     (39,410 )
         
Interest expense     -  
         
LOSS FROM DISCONTINUED OPERATIONS     (39,410 )

 

18

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 15 – SUBSEQUENT EVENTS

 

Discontinued operations

 

Effective March 31, 2019, Natur International Corp closed the offices of its Billings, Montana operations. These operations were discontinued during 2018. During 2018, the Company saw a continued decrease in the utilization of our home healthcare services in Billings, Montana. Additionally, we have seen an increase in competition, specifically for Medicare service providers in 2018. Also, there has been a shortage of Registered Nurses, Physical Therapists and management personnel, leading to higher costs due to having to source the required talent from staffing companies. This increase in costs coupled with a decrease in business activity, lead to the decision to close the Billings, Montana operations. In closing the office, the Company transitioned its clients to new service providers, and terminated employees as the transition happened. The month to month lease will be terminated with the landlord on March 31, 2019. We have one part-time employee, working remotely, primarily on the collection of accounts receivable.

 

Debt restructuring

 

Effective April 9, 2019 the Company and 6 th Wave Efficiency Life Fund have agreed & executed a contract to settle a portion of the amounts owed by the Company to the Holder under the Debt Agreement, including principle, interest expenses, penalties and other charges of whatsoever nature, all in an amount equal to USD 8,846,208 (the “Converted Debt”) in exchange for and in consideration of the issuance to Holder or its designees by the Parent Company of an aggregate of 78,832,399 shares of Class C Preferred Stock (“Debt Repayment Shares”), convertible initially into the equivalent of 78,832,399 shares of Common Stock of the Parent Company (the “Conversion Shares”). The condition precedent to the agreement, the issuance of the Debt Repayment Shares was completed April 9, 2019.

 

The Holder 6 th Wave Efficiency Life Fund agrees that if it sells any of the shares of Common Stock it was directly or beneficially issued by the Parent Company on November 13, 2018, either as shares of Common Stock or the Common Stock underlying the Class B Preferred Stock, in exchange for its equity interest in the Company and any of the Conversion Shares (together the Common Stock, the Common Stock underlying the Class B Preferred Stock and the Conversion Shares are referred to as the “Value Calculation Shares”) at any time prior to December 31, 2022, and the gross proceeds to the Holder or its affiliates from the sale (or deemed sale as provided herein) of any or all of the Value Calculation Shares exceeds USD $15,000,000, then the balance of the Debt, equal to USD $3,000,000 as of the date hereof and any interest, expenses, penalties, and other charges of any nature due thereon under the terms of the Debt Agreement (the “Debt Balance”), will be deemed fully paid, discharged and extinguished and the Debt Agreement in all respects will be terminated and of no further effect.

 

Corporate restructuring

 

In line with the objective to secure the continuity of the company, it was decided late 2018 to extend the product line with added functional extracts (Nutrigenomics, hemp-derived extracts). For this, the company established a NewCo as sister company of Natur Holding BV at March 13, 2019, wholly owned by Natur International Corp. Based on global developments and following the success of companies in the USA and Canada, the company defined new growth objectives with

 

19

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 15 – SUBSEQUENT EVENTS – continued

 

complementary products based on hemp-derived extracts as a new revenue model for this NewCo. Additional funding was sought in the market, but it became apparent that the willingness of new investors to provide the company with funding in debt or equity was dependent on the restructuring of the existing debt on the Balance Sheet of the Company. As most of this debt is held on the Balance Sheet of Natur Holding BV, it was decided to develop a restructuring plan to:

 

  A. To establish an asset transfer from Natur Holding BV to Natur CBD BV, optimizing the proceeds for these assets and subsequently liquidate Natur Holding BV;

 

  B. Continue the business in Natur CBD BV with an extended portfolio of functional products, including food and beverages infused with hemp-derived extracts and deliver the objectives as set by the Board

 

  C. Expeditiously seek new funding in the form of (long-term) or convertible Debt or equity. Discussions with Third parties are on-going. The execution of the intended restructuring program is conditional upon the ability of the company to raise additional capital prior to the implementation of the restructuring plan in order to supply the buying entity of the assets and liabilities with sufficient funds for the asset transaction and the financing of the daily operations. If this condition is not met, the restructuring will fail, and management will be forced to seek legal protection against its creditors and debtholders.

 

The related party loan of Tridutch Holding BV and related party liabilities of STB Family Offices BV and Flare Media BV totaling $1,382,472 were transferred to NL Life Sciences BV at May 8, 2019 as part of a debt transfer agreement.

 

20

 

 

NATUR INTERNATIONAL CORP.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 16 – RECAPITALIZATION

 

As discussed in Note 1 – Organization and nature of business, effective November 13, 2018, Future Healthcare of America entered into a reverse capitalization transaction with Natur Holding BV. In conjunction with the transaction the Company was recapitalized, resulting in the capital structure outlined below. The main purpose of the merger is to raise additional capital for the purposes of growth. The historical number of common shares presented in our financial statements were converted to post merger shares on a 1 to 112 basis. As part of the recapitalization net assets of $1.9 million.

 

The following shares of common stock were issued subsequent to the reverse capitalization. Natur shareholders had a controlling voting percentage of 94% subsequent to the reversed merger:

 

- 115,759,999 shares of common stock for the Natur shareholders.

- 2,023,562 shares of common stock for release of accrued salaries of management

- 2,469,131 shares of preferred A for a capital investment of $2,000,000 and a debt forgiveness of $1,010,000 and accrued interest of $410,552. The preferred A shares will convert at a ratio of 1 preferred A share to 33 common shares. 

- 100,000 shares of preferred B were issued for Natur shareholders. They will convert at a ratio of 1 preferred B share to 1,000 common shares.

 

NOTE 17 – STOCKHOLDERS’ DEFICIT

 

On November 13, 2018, Future Healthcare of America (“Parent Company”) completed the transactions (the “Share Exchange Transaction”) contemplated by that certain Share Exchange Agreement, among Parent Company and the former shareholders of Natur Holdings, B.V., a Netherlands-based holding company (“Natur”). In connection with the Share Exchange Transaction, the former shareholders of Natur received the equivalent of 215,759,999 shares of the Common Stock of Parent Company (the “Common Stock”), which was issued in part as 115,760,000 shares of Common Stock and in part as 100,000 shares of voting, convertible Series B Preferred Stock of Parent Company (the “Series B Preferred Stock”) representing 100,000,000 shares of Common Stock upon conversion. The Series B Preferred Stock will convert automatically upon Parent Company increasing the number of shares of Common Stock of its authorized capital in sufficient amount to permit the conversion of the Series B Preferred Stock, which it plans to do promptly so as to cause the conversion of the Series B Preferred Stock. Immediately after the Share Exchange Transaction, the former Natur shareholders collectively have a controlling position among the shareholders of Parent Company, and Natur has become a wholly-owned subsidiary of Parent Company. At closing the number of common shares, issued and outstanding was 129,049,192.

 

On September 21, 2018, Parent Company also executed a Securities Purchase Agreement (the “SPA”) by which it agreed to privately issue and sell to Alpha Capital Anstalt (the “Alpha”) 2,469,131 shares of non-voting, convertible Series A Preferred Stock, each share convertible into approximately 33 shares of Common Stock at the rate of $.030303. Alpha also purchased two warrants, one pursuant to the SPA that is exercisable for 33,000,000 shares of Common Stock at $.060606 per share and one pursuant to a debt cancellation agreement exercisable for 6,000,000 shares of Common Stock at $.15 per share. The aggregate purchase price for the Series A Preferred Stock and the two warrants was $2,000,000 in cash and conversion of approximately $769,000 of debt and interest due Alpha from Parent Company under a prior loan agreement. Prior to the acquisition of Natur, Alpha also cancelled approximately $651,000 of debt principle and interest due from Parent Company. These transactions eliminated $1,420,000 of debt principle and interest of Parent Company and improved its balance sheet. As part of the SPA transaction, Alpha has also agreed to reimburse up to $100,000 of the liabilities of Parent Company existing at the closing date.

 

On March 19, 2019, the holder of the Series A Preferred Stock converted 72 of such shares with a stated value of $72,000 for 2,376,002 shares of common stock. The applicable conversion price was $0.030303. The company did not receive any payment on this conversion, having received the consideration for the Series A Preferred Shares on November 12, 2018. There are remaining an aggregate of 2,397.131 shares of Series A Preferred Stock issued and outstanding. The shares of common stock issued on conversion are registered for resale by the holder.

 

21

 

 

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

General

 

Safe Harbor Statement .

 

Statements made in this Form 10-Q which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company, including, without limitation, (i) our ability to gain a larger share of the home healthcare industry, our ability to continue to develop services acceptable to our industry, our ability to retain our business relationships, and our ability to raise capital and the growth of the home healthcare industry, and (ii) statements preceded by, followed by or that include the words “may”, “would”, “could”, “should”, “expects”, “projects”, “anticipates”, “believes”, “estimates”, “plans”, “intends”, “targets”, “tend” or similar expressions.

 

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Company’s control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following, in addition to those contained in the Company’s reports on file with the Securities and Exchange Commission: general economic or industry conditions, nationally and/or in the communities in which the Company conducts business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, changes in the home healthcare industry, the development of services that may be superior to the services offered by the Company, competition, changes in the quality or composition of the Company’s services, our ability to develop new services, our ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting the Company’s operations, services and prices.

 

Accordingly, results actually achieved may differ materially from expected results in these statements.  Forward-looking statements speak only as of the date they are made.  The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

 

NTRU New Vision & Mission

 

Natur is committing to meet the demands of the burgeoning market for healthy food & beverage products beyond our award-winning fruit and vegetable juices and snacks. The Company is preparing for launch of a wider range of foods and beverages that are effectively functional. With consumers in increasing numbers eating more frequently, eating socially and being focused on the wellness derived from their choices, Natur is offering choices that can boost their immune system, support a sense of equilibrium in a stressful life, help to resist foods that are not healthy, and more.

 

Natur brings the forces of nature, existing naturally and organically, as functional supplements in our branded foods and beverages. The first of nature’s superfoods to join our line is hemp. We are preparing for launch in the Spring of our line of juices and snacks infused with hemp-derived extracts that are intended to offer improvement in quality of life. The human body’s endo-cannabinoid system is starved for sources of external cannabinoids. When fed, this system fires up the forces of immunity, pain management, heart health, a sense of equilibrium and much more. The Forces of Nature, from the industrial hemp plant, in their purest form, provide the best source for these important cannabinoids. These hemp-derived extracts are the non-psychoactive cannabinoid in the hemp plant that, in increasing numbers, is gain consumer fans for its potential role in treating many common health issues, including pain, inflammation, anxiety, depression, acne and heart disease.

 

Anticipating growing demand, Natur is developing collaborations in hemp cultivation, extraction and innovation – with growers, greenhouses, research and development scientists driving new products in the fields of hemp-derived medication, edibles and beverages, human and animal topicals and wellness products.

 

22

 

 

Share Option Agreements

 

The 2019 Plan provides for grants of both incentive stock options, or “ISOs”, which are subject to special income tax treatment, and non-statutory options, or “NSOs.” Eligibility for ISOs is limited to employees of the Company and its subsidiaries. The exercise price of an ISO cannot be less than the fair market value of the common stock at the time of grant. In addition, the expiration date of an ISO cannot be more than ten years after the date of the original grant. In the case of NSOs, the exercise price and the expiration date are determined in the discretion of the administrator. The administrator also determines all other terms and conditions related to the exercise of an option, including the consideration to be paid, if any, for the grant of the option, the time at which options may be exercised and conditions related to the exercise of options.

 

The 2019 Plan also provides for awards of shares of restricted common stock. Awards of restricted stock may be made in exchange for past services or other lawful consideration. Generally, awards of restricted stock are subject to the requirement that the shares be forfeited or resold to the Company unless specified conditions are met. Subject to these restrictions, conditions and forfeiture provisions, any recipient of an award of restricted stock will have all the rights of a stockholder of the Company, including the right to vote the shares and to receive dividends. The 2019 Plan also provides for deferred grants (“deferred stock”) entitling the recipient to receive shares of common stock in the future on such conditions as the administrator may specify.

 

Amendment to Articles of Incorporation

 

On April 4, 2019, the Company filed an Articles of Amendment in the State of Wyoming to create a new class of Series C Preferred Stock, which was returned as of April 9, 2019. The Series C Preferred Stock has a liquidation preference of $112.20 per share. Each share of Series C Preferred Stock may be converted into 1,000 shares of Common Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization) without the payment of any additional consideration by the holders thereof. The Series C Preferred Stock automatically converts into 78,832,399 shares of Common Stock upon the six-month anniversary of the Conversion Agreement if there has been an increase in the common stock capitalization of the Company. The holders of Series C Preferred Stock are entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C Preferred Stock are convertible on all matters presented to the shareholders.

 

Business Highlights

 

During the quarter ended March 31, 2019, the Company completed seating its newly installed board of directors and appointed a new Chief Executive Officer, adopting a fresh direction for the Company. Practical decisions were made with regard to the existing business and customer base based on the contribution to the new vision and mission and to profitability.

 

For the quarter, while sales revenues were considerably lower year over year, operating losses were also lower. Contributing to negative margins was the reduction of inventories through liquidation.

 

Results of Operations and Financial Condition

 

Three Months Ended 31 March, 2019 versus Three Months Ended 31 March 2018

 

During the three months ended March 31, 2019, Natur recorded revenues of $64,419, an 88% decrease over revenues of $527,717 for the same period in 2018. The decrease in 2019 is attributed to the decision the company made to discontinue selling to less profitable customers while developing its new culturally relevant product lines. It should be noted that in Q1 2018, the introduction of two large customers generated initial opening orders, filling the supply chain. Both of these customers proved to be less beneficial to the business than planned and by the beginning of Q1 2019 sales to these customers were discontinued.

 

With the lower revenues in the quarter, cost of goods sold included unleveraged warehousing, inventory reduction and product discard costs and totaled $94,777, a 65% decrease as compared to $273,752 in the comparable period of 2018. Natur posted a gross loss of $30,358 during the first quarter 2019, versus a gross profit of $253,965 for the first quarter of 2018.

 

23

 

 

Natur made year over year improvements in some controllable costs while recording total operating expenses of $1,939,328 during the first quarter of 2019, a 17% increase as compared to operating expenses of $1,611,564 in the same period of 2018. Wages & Salaries showed improvement, totaling $264,729 in the first quarter of 2019 versus $443,381 in the first quarter 2018, a decrease of 40% driven by significantly streamlined head-count compared to Q1 of 2018. A contributing factor is the discontinuation of retail store activities in the UK and the Netherlands. Selling, General & Administrative costs increased to $1,402,410 from $1,114,867 when comparing the first quarter of 2019 versus 2018, or 26%. This was driven mainly by an increase in the overall costs incurred by the business due to the administration costs of maintaining a public listing such as legal, board & accountancy fees. The company also introduced a stock option scheme in 2019 with no similar such costs in the first quarter of 2018. Amortization & Depreciation costs increased to $272,189 from $53,316 when comparing the first quarter of 2019 versus 2018, or 411%. This was driven mainly by the company taking a prudent measure to write down all assets in the retail stores (roughly $200k) to Nil. As the company cannot comfortably assume we will receive any proceeds for these assets it will therefore only take gains on disposal in future periods should they be realized.

 

Natur’s net loss available to common shareholders was $1,747,531 for the first quarter of 2019.  This represents a 20% decrease from our net loss of $2,179,184 in the first quarter of 2018. The decrease in the loss was partially offset due to the liquidation of the UK business which allowed a gain on disposal of $300,798 to be realized.

 

Three Months Ended 31 March, 2019 versus Three Months Ended 31 December 2018

 

During the three months ended March 31, 2019, Natur recorded revenues of $64,419, a 63% decrease over revenues of $173,378 for the preceding period. The decrease for 2019 was driven by the fact that in Q4 2018 we received wind-down revenues from two former customers of $102,000. We have received no such orders in Q1 2019 due to the strategic focus change of the business.

 

For the quarter ended March 31, 2019, cost of goods sold totaled $94,777, a 48% decrease as compared to $183,777 in the preceding period of 2018. This reflects the costs associated with the overall reduction of revenue and due to the reduction in sales the company has experienced higher marginal costs for our warehousing. We have also experienced higher disposal costs due to the perishable nature of our products. Natur posted a gross loss of $30,358 during the first quarter 2019, versus a gross loss of $10,039 for the preceding quarter of 2018.

 

Natur recorded total operating expenses of $1,939,328 during the first quarter of 2019, a 17% increase as compared to operating expenses of $1,598,974 in the preceding period.  Wages & Salaries totaled $264,729 in the first quarter of 2019 versus $267,511 in the preceding quarter a decrease of 1%. Selling, General & Administrative costs increased to $1,402,410 from $1,279,731 when comparing the preceding quarter, or 21%. This was driven mainly by an increase in the overall costs incurred by the business due to the administration costs of maintaining a public listing such as legal & accountancy fees. The company also introduced a stock option scheme in 2019 with no similar such costs in the last quarter of 2018. Amortization & Depreciation costs increased to $272,189 from $51,732 when comparing the first quarter of 2019 versus the fourth quarter of 2018, or 426%. This was driven mainly by the company taking a prudent measure to write down all assets in the retail stores (roughly $200k) to Nil. As the company cannot comfortably assume we will receive any proceeds for these assets it will therefore only take gains on disposal in future periods should they be realized.

 

Natur’s net loss available to common shareholders was $1,747,531 for the first quarter of 2019.  This represents a 21% increase from our net loss of $2,144,114 in the last quarter of 2018. The increase in the loss was partially offset due to the liquidation of the UK business which allowed a gain on disposal of $300,798 to be realized.

 

Restructuring Activities

 

Debt restructuring - Effective April 9, 2019 the Company and 6th Wave Efficiency Life Fund have agreed & executed a contract to settle a portion of the amounts owed by the Company to the Holder under the Debt Agreement, including principle, interest expenses, penalties and other charges of whatsoever nature, all in an amount equal to USD 8,846,208 (the “Converted Debt”) in exchange for and in consideration of the issuance to Holder or its designees by the Parent Company of an aggregate of 78,832,399 shares of Class C Preferred Stock (“Debt Repayment Shares”), convertible initially into the equivalent of 78,832,399 shares of Common Stock of the Parent Company (the “Conversion Shares”). The condition precedent to the agreement, the issuance of the Debt Repayment Shares was completed April 9, 2019.

 

24

 

 

The company has made further agreements, subject to board approval, confirming to agree to the principle of debt conversion to shares of the company to the following debtholders:

 

Name of debtholder   Currency     Amount in Euros     USD/EURO     Amount of debt in $     price per share in $     number of shares     Type of
share
 
6th Wave Efficiency Life Fund   USD                       3,450,000       0.05       69,000,000       preferred  
Dam! Holding BV   EUR       505,487       1.12       566,145       0.05       11,264,700       common  
Ghassan Akeel   USD                       571,236       0.055       11,632,445       common  
NL Life Sciences BV   EUR       2,020,000       1.12       2,262,400       0.0303031       74,659,028       preferred  
STB Family Office SARL   EUR       202,877       1.12       227,222       0.0303031      

7,498,309

      preferred  
            2,728,364               7,077,004               174,054,490          

 

Corporate restructuring - In line with the objective to secure the continuity of the company, it was decided late 2018 to extend the product line with added functional extracts (Nutrigenomics, hemp-derived). For this, the company established a NewCo as a sister company of Natur Holding BV at March 13, 2019, wholly owned by Natur International Corp. Based on global developments and following the success of companies in the USA and Canada, the company defined new growth objectives with complementary products based on hemp-derived extracts as a new revenue model for this NewCo. Additional funding was sought in the market, but it became apparent that the willingness of new investors to provide the company with funding in debt or equity was dependent on the restructuring of the existing debt on the Balance Sheet of the Company. As most of this debt is held on the Balance Sheet of Natur Holding BV, it was decided to develop a restructuring plan to: 

 

  A. To establish an asset transfer from Natur Holding BV to Natur CBD BV, optimizing the proceeds for these assets and subsequently liquidate Natur Holding BV;

 

  B. Continue the business in Natur CBD BV with an extended portfolio of functional products, including infused food and beverages with hemp-derived extracts and deliver the objectives as set by the Board

 

  C. Expeditiously seek new funding in the form of (long-term) or convertible Debt or equity. Discussions with Third parties are on-going. The execution of the intended restructuring program is conditional upon the ability of the company to raise additional capital prior to the implementation of the restructuring plan in order to supply the buying entity of the assets and liabilities with sufficient funds for the asset transaction and the financing of the daily operations. If this condition is not met, the restructuring will fail, and management will be forced to seek legal protection against its creditors and debtholders.

 

Accounting Policies

 

ASC 842: In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. This update requires the recognition of lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous guidance. The accounting for finance leases (capital leases) was substantially unchanged. The original guidance required application on a modified retrospective basis with adjustments to the earliest comparative period presented. In August 2018, the FASB issued ASU No. 2018-11, “Targeted Improvements to ASC 842,” which included an option to not restate comparative periods in transition and elect to use the effective date of ASU No. 2016-02 as the date of initial application, which the Company elected. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, and continues to be reported under previous guidance that did not require the recognition of operating lease liabilities and corresponding lease assets on the consolidated balance sheet. As a result of the adoption of ASU No. 2016-02 on January 1, 2019, the Company recorded operating lease right-of-use assets of $580,310 and operating lease liabilities of $578,007. The adoption of ASU No. 2016-02 had an immaterial impact on the Company’s condensed consolidated statement of income and consolidated statement of cash flows for the three-month period ended March 31, 2019. In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company to carry forward the historical lease classification, not reassess prior conclusions related to expired or existing contracts that are or that contain leases, and not reassess the accounting for initial direct costs.

 

25

 

 

Quantitative and Qualitative Disclosures About Market Risk .

 

Not required for smaller reporting companies.

 

Controls and Procedures .

 

(a)  Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)), which we refer to as disclosure controls, are controls and procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any control system. A control system, no matter how well conceived and operated, can provide only reasonable assurance that its objectives are met. No evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

As of March 31, 2019, an evaluation was carried out under the supervision and with the participation of our management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls.  Based upon that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that, as of such date, the design and operation of these disclosure controls were effective to accomplish their objectives at the reasonable assurance level.

 

(b) Changes in Internal Control over Financial Reporting

 

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), occurred during the fiscal quarter ended March 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting

 

26

 

 

PART II - OTHER INFORMATION

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included in Part I, Item 1 of this Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.” Our actual results may differ materially from those described below. You should read the “Risk Factors” section of this Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

Certain figures, such as interest rates and other percentages included in this section have been rounded for ease of presentation. Percentage figures included in this section have not in all cases been calculated on the basis of such rounded figures but on the basis of such amounts prior to rounding. For this reason, percentage amounts in this section may vary slightly from those obtained by performing the same calculations using the figures in our consolidated financial statements or in the associated text. Certain other amounts that appear in this section may similarly not sum due to rounding.

 

ITEM 1 – LEGAL PROCEEDINGS

 

On June 17, 2016 and June 30, 2016 two complaints were filed, one with the Federal Equal Employment Opportunity Commission (“EEOC”) and one with the Wyoming State Department of Labor against the Company, alleging discrimination on the basis of sex and disability. The complaints did not seek any specific monetary relief. The complaints were mediated by the Wyoming State Department of Labor, and the U.S. Equal Employment Opportunity Commission. The Wyoming State Department of Labor issued a notice of dismissal for one of the complaints. After reviewing the facts and circumstances, the Company believes the claims made are weak, at best, and the Company has retained counsel and intends to continue a vigorous defense. On March 6, 2018, a complaint was filed with the Wyoming Court of Natrona County, alleging violation of the Wyoming Fair Employment Practices Act of 1965 for discrimination based upon sex, disability and retaliation. The complaint does not seek any specific monetary relief. At this time, management cannot reasonably estimate the cost to defend or the outcome of the complaints.

 

On June 1, 2018, The U.S. EEOC made a determination that Interim Healthcare of Wyoming violated the Wage discrimination laws (Title VII of the Civil Rights Act of 1964) by paying a male employee more than female employees. The EEOC initially claimed that back wages for these individuals plus liquidated damages total $43,593. On September 19, 2018, the Company attended a Conciliation meeting, at which the EEOC presented a revised settlement of $133,575 for back wages plus liquidated damages. The Company and the EEOC did not agree to a resolution. On September 28, 2018, the EEOC filed in the U.S. District Court for the District of Wyoming a complaint claiming Interim Healthcare of Wyoming violated the Wage discrimination laws (Title VII of the Civil Rights Act of 1964) by paying a male employee more than female employees. It is too early to provide an educated opinion on the chances of a favorable outcome in this matter. There was a wage disparity present at Interim such that a male RN nurse employee was earning $1-$2 more per hour than all other RN nurse employees who were female. Interim employed approximately 6 female RN nurses, and this wage disparity existed for approximately 1 year of operation. We have asserted that this wage disparity was the result of market factors and not illegal gender discrimination, however whether we will be able to marshal sufficient evidence to overcome the presumption that arises from the admitted wage disparity. The Company recorded an accrual totaling $133,575 related to this matter.

 

27

 

 

ITEM 1A – RISK FACTORS

 

Not required for smaller reporting companies.

 

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None, not applicable.

 

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

 

None, not applicable.

 

ITEM 4 – MINE SAFETY DISCLOSURES

 

None, not applicable.

 

ITEM 5 – OTHER INFORMATION

 

ITEM 6 – EXHIBITS

 

Exhibit No.   Description
     
31.1   302 Certification of Robert A. Paladino
     
31.2   302 Certification of Ellen Berkers
     
32   906 Certification.
     
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema
101.CAL   XBRL Taxonomy Extension Calculation
101.DEF   XBRL Taxonomy Extension Definition
101.LAB   XBRL Taxonomy Extension Labels
101.PRE   XBRL Taxonomy Extension Presentation Linkbase

 

28

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NATUR INTERNATIONAL CORP.
     
Date: 15/5/19 By: /s/ Robert A. Paladino
    Robert A. Paladino
    Chief Executive Officer
     
Date: 15/5/19   /s/ Ellen Berkers
    Ellen Berkers
    Chief Financial Officer

 

 

29

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Robert A. Paladino, certify that:

1.   I have reviewed this report on Form 10-Q of the issuer;

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

 

4.   The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the  issuer and have:

 

a)   designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

b)   designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)   evaluated the effectiveness of the issuer's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)   disclosed in this report any change in the issuer's internal control over financial reporting that occurred during the issuer's most recent fiscal quarter (the issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the  issuer's internal control over financial reporting; and

 

5.   The issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer's auditors and the audit committee of the issuer's board of directors (or persons performing the equivalent functions);

 

a)   all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer's ability to record, process, summarize and report financial information; and

 

b)   any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer's internal control over financial reporting.

 

Date: 5/15/19 By:  /s/ Robert A. Paladino
    Robert A. Paladino
Chief Executive Officer

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ellen Berkers, certify that:

1.   I have reviewed this report on Form 10-Q of the issuer;

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

 

4.   The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the  issuer and have:

 

a)   designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

b)   designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)   evaluated the effectiveness of the issuer's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)   disclosed in this report any change in the issuer's internal control over financial reporting that occurred during the issuer's most recent fiscal quarter (the issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the  issuer's internal control over financial reporting; and

 

5.   The issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer's auditors and the audit committee of the issuer's board of directors (or persons performing the equivalent functions);

 

a)   all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer's ability to record, process, summarize and report financial information; and

 

b)   any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer's internal control over financial reporting.

 

Date: 5/15/19 By:  /s/ Ellen Berkers
    Ellen Berkers
Chief Financial Officer

 

Exhibit 32

 

CERTIFICATION PURSUANT TO SECTION 1350,

CHAPTER 63 OF TITLE 18, UNITED STATES CODE,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q for the period ended March 31, 2019 (the “Report”) of Natur International Inc. (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, we, Robert Paladino, the Chief Executive Officer and Ellen Berkers, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

  By:  /s/ Robert Paladino
Date: May 15, 2019   Name: Robert Paladino, Chief Executive Officer

 

  By:  /s/ Ellen Berkers
Date: May 15, 2019   Name: Ellen Berkers, Chief Financial Officer